gossypol has been researched along with Prostatic Neoplasms, Castration-Resistant in 3 studies
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.
Prostatic Neoplasms, Castration-Resistant: Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, R | 2 |
| Wu, M | 1 |
| Cao, T | 1 |
| Luo, K | 1 |
| Huang, F | 1 |
| Huang, Z | 1 |
| Zhou, J | 1 |
| Wang, Y | 1 |
| Zhu, S | 1 |
| Sonpavde, G | 2 |
| Pond, GR | 2 |
| Armstrong, AJ | 2 |
| Galsky, MD | 2 |
| Leopold, L | 2 |
| Wood, BA | 2 |
| Wang, SL | 1 |
| Paolini, J | 1 |
| Chen, I | 1 |
| Chow-Maneval, E | 1 |
| Mooney, DJ | 1 |
| Lechuga, M | 1 |
| Smith, MR | 1 |
| Michaelson, MD | 1 |
2 trials available for gossypol and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxe | 2014 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Hu | 2013 |
1 other study available for gossypol and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Identification of the gossypol derivatives as androgen receptor inhibitor.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Cell Line, Tumor; Drug Resistance, Neoplasm; Go | 2022 |